- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 22, 2013 | 10:35 AM EDT
Well buy this industrial on a pullback and build our position in a healthcare stock. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 22, 2013 | 10:27 AM EDT
The stock has doubled over the past three months and we don't want to be greedy with our gains. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 22, 2013 | 10:20 AM EDT
With the stock trading lower today, we have decided to be prudent and sell some shares from this One-rated name. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Perrigo Company (PRGO)
PRGO (NASDAQ:Drugs)
$117.71
-0.94
-0.79%
Today's Range: 117.46 - 120.44 |
PRGO Avg Daily Volume: 511,700
| Last Update: 05/22/13 - 2:16 PM EDT |
| Volume: 270,716 |
| YTD Performance: 14.42% |
| Open: $119.01 |
| Previous Close: $118.65 |
| 52 Week Range: $98.79 - $121.33 |
| Oustanding Shares: 94,039,071 |
| Market Cap: 11,193,470,621 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 10 | 8 | 8 | 7 |
| Moderate Buy | 2 | 2 | 2 | 2 |
| Hold | 4 | 5 | 5 | 6 |
| Moderate Sell | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.74 | 1.91 | 1.91 | 2.03 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (06/13) | FY (06/14) | |
|---|---|---|---|---|
| Average Estimate | $1.58 | $1.47 | $5.61 | $6.62 |
| Number of Analysts | 16 | 8 | 16 | 16 |
| High Estimate | $1.66 | $1.61 | $5.70 | $6.78 |
| Low Estimate | $1.51 | $1.22 | $5.55 | $6.20 |
| Prior Year | $1.28 | $1.27 | $4.99 | $5.61 |
| Growth Rate (Year over Year) | 23.10% | 15.94% | 12.53% | 17.95% |
zweitgeist4: @FoxonStocks $TSLA $SCTY $LEN $PHM $HOV $ROST $OCN $NSM $GOOG $URI $REGN $PCYC $MDSO $CHD $LL $DATA $DPZ $N $PRGO $EXR $HD $ENB $SPWR $JASO
2 days ago from web
2 days ago from web
SeekingAlpha: 2 Healthcare Companies And 1 Consumer Goods Company With Recent Intensive Insider Selling http://t.co/T7j4lpu7mc $DLPH $PRGO $REGN
2 days ago from Seeking Alpha
2 days ago from Seeking Alpha
micenter: Perrigo $PRGO Could Fall Through $118.93 Support Level ( http://t.co/r3D3F4n49k )
5 days ago from Marketintelligencecenter.com
5 days ago from Marketintelligencecenter.com
BV_Healthcare: $PRGO Perrigo Co Files 8-K : Entry into a Material Definitive Agreement, Financial.. http://t.co/Rwd3XuZCla
6 days ago from BoardVote.com
6 days ago from BoardVote.com
Perrigo initiated Market Perform at Leerink
PRGO was initiated with a Market Perform rating, said Leerink. Valuation is fair based on stable fundamentals and store brand expansion plans. Price target is $124.
Perrigo upgraded at JP Morgan
PRGO was upgraded from Neutral to Overweight, JP Morgan said. Company has multiple growth drivers in place.
Beating the S&P 500 ETF's five-plus-year round trip to record levels.
Perrigo upgraded at UBS
PRGO was upgraded to Buy from Neutral, UBS said. $130 price target. Greater confidence in growth.
The generic drugmaker shows new signs of life after months of struggle.
Perrigo upgraded at Morgan Stanley
PRGO was upgraded from Equal-weight to Overweight, Morgan Stanley said. $125 price target. Nutritionals overhang has been lifted and the company has strong growth prospects.
Perrigo downgraded at Goldman
PRGO was downgraded from Neutral to Sell, Goldman Sachs said. $110 price target. Growth could slow in the next few quarters.
Perrigo downgraded at Caris
PRGO was downgraded from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals.
Perrigo upgraded at Barrington
PRGO was upgraded from Market Perform to Outperform, Barrington said. $142 price target. Company can continue to leverage its competitive advantages.
Now is the time to pop the pharmaceutical pill and buy.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.